Invited and regular paper
Use of an optical biosensor to measure prostate-specific antigen in whole blood

https://doi.org/10.1016/0925-4005(95)01666-XGet rights and content

Abstract

Prostate cancer is the cause of death of many thousands of men worldwide. The screening of men for elevated prostate-specific antigen (PSA) levels is set to play an important role in the diagnosis and management of the disease. At present the screening efficiency of PSA testing is restricted, as estimation are performed in centralized laboratories using serum samples. This paper decribes the development of an assay for the measurement of PSA in whole blood using the fluorescence capillary fill device (FCFD), an optical biosensor technology. The FCFD PSA whole-blood test will meet the requirements of a ‘point-of-care’ diagnostic product suitable for use in prostate cancer screening programmes.

References (15)

There are more references available in the full text version of this article.

Cited by (0)

View full text